{"filing":{"accession_number":"0001171843-26-005405","cik":"0001123494","ticker":"HBIO","company_name":"HARVARD BIOSCIENCE INC","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"f8k_081126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/f8k_081126.htm"},"events":[{"id":26839,"run_id":24410,"accession_number":"0001171843-26-005405","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Harvard Bioscience issued a press release on August 11, 2026, announcing financial results for Q2 2026 and the six-month period ended June 30, 2026, including revenue of $22.7 million (Q2) and $43.5 million (six months), along with updated full-year 2026 guidance raising revenue growth expectations to 3%-5%. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.","company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28112,"accession_number":"0001171843-26-005405","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Harvard Bioscience issued a press release on August 11, 2026, announcing financial results for Q2 2026 and the six-month period ended June 30, 2026, including revenue of $22.7 million (Q2) and $43.5 million (six months), along with updated full-year 2026 guidance raising revenue growth expectations to 3%-5%. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:03:47.524098+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28112,"accession_number":"0001171843-26-005405","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Harvard Bioscience issued a press release on August 11, 2026, announcing financial results for Q2 2026 and the six-month period ended June 30, 2026, including revenue of $22.7 million (Q2) and $43.5 million (six months), along with updated full-year 2026 guidance raising revenue growth expectations to 3%-5%. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:03:47.524098+00:00","company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","filing_date":"2026-08-11"}]}